Effectiveness and Safety of Idarucizumab for Periprocedural Cardiac Tamponade After Catheter Ablation of Atrial Fibrillation in Dabigatran Recipients: A Retrospective Controlled Study-Reference-Cited by-同舟云学术

Effectiveness and Safety of Idarucizumab for Periprocedural Cardiac Tamponade After Catheter Ablation of Atrial Fibrillation in Dabigatran Recipients: A Retrospective Controlled Study

Published:2022-06-18 Issue:5 Volume:22 Page:557-565
ISSN:1175-3277
Container-title:American Journal of Cardiovascular Drugs
language:en
Short-container-title:Am J Cardiovasc Drugs

Author:

Huang Langjing,Yu Zhihua,Liu Mei,Shang Xiaoke

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40256-022-00536-7.pdf

Reference26 articles.

1. Hu ZC, Jiang C, Liu SY, et al. Current status and quality analysis of interventional therapy for patients with atrial fibrillation in China. Zhonghua Xin Xue Guan Bing Za Zhi. 2021;49(3):224–8.

2. Yuan Y, Zhao Q, Li L, et al. Clinical analysis of atrial fibrillation catheter radiofrequency ablation periprocedural cardiac tamponade in the elderly. Chin J Gerontol. 2021;40(2):173–7.

3. Zhou Li, Li H. Progress in the studies of dabigatran ester-specific reversing agent idarucizumab. Chin J Cardiovasc Dis. 2018;46(8):655–7.

4. Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):546–7.

5. National Health Commission Stroke Prevention Expert Committee Atrial Fibrillation Associated Stroke Prevention Subcommittee, Chinese Medical Association Cardiac Electrophysiology and Pacing Chapter, and China Physicians Association Cardiac Arrhythmia Committee. Clinical Expert Consensus on Dabigatran-specific Reversing Agent Idarucizumab. Chin J Cardiac Arrhythmia. 2020;24(2):113–22.